Invokana

Can Invokana Trigger Diabetic Ketoacidosis?

invokanaResearch has shown that taking the diabetes drug Invokana (canagliflozin) can trigger diabetic ketoacidosis, a potentially fatal condition.

Invokana is used to treat Type 2 diabetes. There are more than 450,000 Invokana prescriptions filled every three months in the United States. The drug is made and marketed by Janssen, a partner of Johnson & Johnson. It was the first drug of its kind to treat Type 2 diabetes and drug makers were hopeful it would help patients who did not respond to other diabetes drugs. Sadly, it has been linked to many medical risks, including potentially deadly diabetic ketoacidosis.

Type 2 Diabetes

Type 2 diabetes is a disease that affects the body’s ability to process insulin. The disease affects about nine million Americans. Over time, it can lead to high blood pressure, heart disease, blindness, kidney disease, damage to the feet and hands, and other health problems.

In order for the body to manage sugar and turn it into energy, insulin must help cells absorb it. When this does not happen because of problems with insulin, sugar remains in the blood system, causing blood glucose levels to raise to unhealthy levels. This is why diabetics must pay attention to their blood sugar.

About Invokana

Invokana is part of a group of drugs known as SGLT2 anti-diabetics. It works by preventing glucose from being reabsorbed by the kidneys. It also allows excess sugar to be let out in urine. Studies have shown Invokana users excrete up to 450 calories of extra sugar in urine.

Despite Invokana working for some users, it comes with a variety of side effects. Most are mild and might be a problem with all diabetes medications, including:

  • Yeast infection
  • Urinary tract infection
  • Nausea
  • Fatigue
  • Photosensitivity
  • Increased LDL (bad) cholesterol

One of the biggest concerns for Invokana users is the drug’s link to diabetic ketoacidosis. The risk was so serious that in 2015, the Food and Drug Administration (FDA) issued a warning for Invokana and drugs like it. The warning came after more than 20 SGLT2 inhibitor users reported symptoms of the condition.

Diabetic ketoacidosis occurs when ketone levels rise too high. When glucose cannot be used as energy by the body’s cells, the body needs to break down fat to use for energy. As this occurs, ketones are produced and acid levels in the blood rise too high. Once this happens, it is just a short time before diabetic ketoacidosis becomes a life-threatening ordeal.

What are the Symptoms of Diabetic Ketoacidosis?

  • Intense thirst
  • Increased need to use the bathroom
  • Nausea
  • Fatigue
  • Abdominal pain
  • Fruit-smelling breath odor
  • Shortness of breath

More advanced symptoms include:

  • Confusion
  • Vomiting
  • Trouble breathing
  • Dizziness or fainting
  • Unconsciousness

In addition to diabetic ketoacidosis, Invokana can also cause problems with blood pressure, interferes with the kidneys, and might trigger allergic reactions. The FDA has also expressed concerns over Invokana’s ability to increase users’ risk for heart attack since it raises LDL cholesterol levels.

The consumer safety group Public Citizen has asked the FDA to limit certain ad methods for Invokana, including claims the drug could help with weight loss and lower blood pressure.

Invokana Lawsuits

Invokana users who have suffered side effects might be able to get a legal settlement to help them with medical costs, lost wages, and pain and suffering. Many have needed to go to the hospital and receive long-term medical care.

Those who have lost loved ones due to Invokana use are also encouraged to contact a legal expert to determine if money is available. Settlements have already occurred in diabetes drugs lawsuits and the same could happen for Invokana users. If you or a loved one has been injured by Invokana use, it’s important you take action as soon as possible.

View Sources
  1. American Diabetes Association, (2015) Living with Diabetes, Complications: Ketoacidosis, ADA Diabetes.org, Accessed on 04 June 2015 http://www.diabetes.org/living-with-diabetes/complications/ketoacidosis-dka.html
  2. American Diabetes Association, (10 June 2014), Statistics About Diabetes, ADA Diabetes.org, Accessed on 04 June 2015 http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav
  3. Berkot, B., (15 May 2015), FDA warns on newer class of type 2 diabetes drugs, Reuters, Accessed on 04 June 2015 http://www.reuters.com/article/2015/05/15/us-fda-diabetes-idUSKBN0O01P520150515
  4. Brooks, M., (15 May 2015), SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA, Medscape Pharmacists, Accessed on 04 June 2015 http://www.medscape.com/viewarticle/844754
  5. Drugs.com, Invokana Prescribing Information, Drugs.com, Accessed on 04 June 2015 http://www.drugs.com/pro/invokana.html
  6. Fiore, K., SGLT2 Inhibitors May Up Glucose Production, MedPage Today, Accessed on 04 June 2015 http://www.medpagetoday.com/Endocrinology/Diabetes/44014
  7. Food and Drug Administration (15 May 2015), FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, U.S. Food and Drug Administration, Accessed on 04 June 2015 http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
  8. Hahn, P., (19 August 2014), Part 2: "IT'S A NIGHTMARE": After the Avandia debacle, is history about to repeat itself?, Canada Free Press, Accessed on 04 June 2015 http://canadafreepress.com/index.php/article/65394
  9. Huston, L., (29 March 2013), FDA Approves First SGLT2 Inhibitor For Diabetes, Forbes, Accessed on 04 June 2015 http://www.forbes.com/sites/larryhusten/2013/03/29/fda-approves-first-sglt2-inhibitor-for-diabetes/
  10. Janssen Pharmaceutica (26 May 2014) First-in-Class Type 2 Diabetes Medication Approved in Canada - INVOKANA offers a new approach to treatment, Janssen.ca, Accessed on 04 June 2015 http://www.janssen.ca/subcategory_docdownload?id=sites/default/files/about_us_media/INVOKANA%20Launch%20News%20Release%20FINAL.pdf
  11. LaMattina, J., (13 April 2015), Should the FDA Require CV Outcome Studies for Diabetes Drugs Before Approval? Forbes, Accessed on 04 June 2015 http://www.forbes.com/sites/johnlamattina/2015/04/13/should-the-fda-require-cv-out come-studies-for-diabetes-drugs-before-approval/
  12. MacDonald, E., (01 April 2015), FDA Urged to Fine Drugmakers Over Ads, FoxBusiness, Accessed on 04 June 2015 http://www.foxbusiness.com/economy-policy/2015/04/01/fda-urged-to-fine-drugmakers-over-ads/
  13. Matsuyama, K., et al (2013, January 28). Takeda jumps after winning FDA approval for diabetes drug. Bloomberg. Retrieved from http://www.bloomberg.com/news/2013-01-28/takeda-diabetes-drug-succeeding-actos-wins-fda-approval.html
  14. Mayo Clinic Staff (12 October 2012), Diabetic Ketoacidosis, Mayo Clinic, Accessed on 04 June 2015 http://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/basics/complications/con-20026470
  15. Mayo Clinic Staff, (24 July 2014), Type 2 diabetes, Treatments and drugs, Mayo Clinic, Accessed on 04 June 2015 http://www.mayoclinic.org/diseases-conditions/type-2-diabetes/basics/treatment/con-20031902
  16. Public Citizen, (10 January 2013), FDA Should Reject Dangerous Diabetes Medication, Public Citizen Tells Advisory Committee, Public Citizen, Accesse on 04 June 2015 http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=3793
  17. Rodale, M., (06 April 2014), The Worst New Drug of 2014, Huffington Post, Accessed on 04 June 2015 http://www.huffingtonpost.com/maria-rodale/the-worst-new-drug-of-201_b_4723514.html
  18. Sun, L., (15 January 2014), 3 ways Johnson & Johnson is Revolutionizing Diabetes, Motley Fool, Accessed on 04 June 2015 http://www.fool.com/investing/general/2014/01/15/3-ways-johnson-johnson-is-revolutionizing-diabetes.aspx
  19. Tauchi, K., Accessed on 04 June 2015, 10 deaths reported following use of newly marketed diabetes drugs, The Asahi Shimbun, Accessed on 04 June 2015 http://ajw.asahi.com/article/behind_news/social_affairs/AJ201501090058
  20. Team, T., (20 May 2015), FDA’s New Warning About Invokana May Not Matter Much For J&J; Let's Focus On Pipeline Instead, Forbes, Accessed on 04 June 2015 http://www.forbes.com/sites/greatspeculations/2015/05/20/fdas-new-warning-about-invokana-may-not-matter-much-for-jj-lets-focus-on-pipeline-instead/
  21. Thomas, K., FDA Advisory Panel Votes to Approve Diabetes Drug, New York Times, Accessed on 04 June 2015 http://www.nytimes.com/2013/01/11/business/fda-advisory-panel-votes-to-approve-diabetes-drug.html?partner=rss&emc=rss&_r=0